Circulating cell death products predict clinical outcome of colorectal cancer patients

[1]  Alexei Degterev,et al.  Expansion and evolution of cell death programmes , 2008, Nature Reviews Molecular Cell Biology.

[2]  R. Johnson,et al.  Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.

[3]  S. Linder,et al.  Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy , 2007, Clinical Cancer Research.

[4]  S. Linder,et al.  The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. , 2007, Lung cancer.

[5]  Brian Keith,et al.  Hypoxia-Inducible Factors, Stem Cells, and Cancer , 2007, Cell.

[6]  M. Ranson,et al.  Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma , 2007, Cancer Chemotherapy and Pharmacology.

[7]  G. Kramer,et al.  Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles , 2006, British Journal of Cancer.

[8]  P. Stieber,et al.  Apoptotic markers in cancer. , 2004, Clinical biochemistry.

[9]  Moonil Kim,et al.  Hypoxia Inhibits Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Blocking Bax Translocation , 2004, Cancer Research.

[10]  Crispin J. Miller,et al.  Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance , 2004, Molecular and Cellular Biology.

[11]  G. Kramer,et al.  Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18 , 2004, Cancer Research.

[12]  H. Hollema,et al.  Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas , 2004, Histopathology.

[13]  J. Wood,et al.  A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera , 2003, Apoptosis.

[14]  S. Linder,et al.  Measurement of an apoptotic product in the sera of breast cancer patients. , 2003, European journal of cancer.

[15]  K. Wiman,et al.  A Novel High-Through-Put Assay for Screening of Pro-Apoptotic Drugs , 2002, Investigational New Drugs.

[16]  A. Cheung,et al.  Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase‐related M30 CytoDeath antibody , 2001, Histopathology.

[17]  B. Persson,et al.  Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis , 1999, The Journal of pathology.

[18]  C. Hauser,et al.  Oncogene activation of human keratin 18 transcription via the Ras signal transduction pathway. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[20]  H. Hollema,et al.  Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. , 2003, Critical reviews in oncology/hematology.